Published in Obstet Gynecol on January 01, 1988
Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One (2012) 1.31
Chromogranin A (CgA) as poor prognostic factor in patients with small cell carcinoma of the cervix: results of a retrospective study of 293 patients. PLoS One (2012) 0.88
Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients. BMC Cancer (2014) 0.86
A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix. Mol Clin Oncol (2013) 0.82
Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy. Gynecol Oncol Rep (2015) 0.81
Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery. Rare Tumors (2011) 0.81
Pap smear screening for small cell carcinoma of the uterine cervix: a case series and review of the literature. J Gynecol Oncol (2011) 0.79
Small cell carcinoma of the uterine cervix in pregnancy: A case report and review of the literature. Oncol Lett (2014) 0.79
Small cell neuroendocrine carcinoma of the cervix: a rare entity. J Clin Diagn Res (2014) 0.77
Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. Oncol Lett (2011) 0.77
Large cell neuroendocrine carcinoma of female genital tract: a clinicopathological study of two cases with review of literature. Indian J Surg Oncol (2013) 0.75
Neuroendocrine carcinoma of the cervix presenting as intractable hyponatremic seizures due to paraneoplastic SIADH-a rare case report and brief review of the literature. Ecancermedicalscience (2014) 0.75
[Neuroendocrine carcinoma of the cervix: a case report and review of the literature]. Pan Afr Med J (2017) 0.75
Cloning vectors that yield high levels of single-stranded DNA for rapid DNA sequencing. Gene (1984) 5.41
Open reading frame expression vectors: a general method for antigen production in Escherichia coli using protein fusions to beta-galactosidase. Proc Natl Acad Sci U S A (1983) 3.09
Promoter mutations in the transfer RNA gene tyrT of Escherichia coli. Proc Natl Acad Sci U S A (1979) 2.89
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
A previously unidentified gene in the spc operon of Escherichia coli K12 specifies a component of the protein export machinery. Cell (1982) 2.84
A shuttle vector plasmid for studying carcinogen-induced point mutations in mammalian cells. Gene (1985) 2.41
Bacteriophage lambda cloning system for the construction of directional cDNA libraries. Proc Natl Acad Sci U S A (1987) 2.39
RNA polymerase interactions with the upstream region of the E. coli tyrT promoter. Cell (1983) 2.34
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst (1996) 2.30
Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol (1994) 2.14
Fusions of the lac operon to the transfer RNA gene tyrT of Escherichia coli. J Mol Biol (1979) 2.03
Isolation and characterization of delta ompB strains of Escherichia coli by a general method based on gene fusions. J Bacteriol (1985) 1.99
Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol (1988) 1.95
Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer (1991) 1.85
Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol (1992) 1.77
Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst (1996) 1.76
Selection of lac gene fusions in vivo: ompR-lacZ fusions that define a functional domain of the ompR gene product. J Bacteriol (1984) 1.74
Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol (1998) 1.71
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol (1994) 1.69
Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol (1994) 1.68
Use of gene fusions to isolate promoter mutants in the transfer RNA gene tyrT of Escherichia coli. J Mol Biol (1979) 1.68
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol (1989) 1.67
Screening in ovarian cancer. Am J Obstet Gynecol (1991) 1.64
Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention. Am J Obstet Gynecol (1994) 1.57
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1985) 1.56
Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol (1994) 1.56
Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics (2000) 1.55
Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol (1994) 1.55
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res (2001) 1.55
Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol (1972) 1.52
Effects of early postoperative chemotherapy on wound healing. Obstet Gynecol (1992) 1.49
Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol (1993) 1.47
Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (1997) 1.45
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet Epidemiol (1996) 1.45
Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2000) 1.44
A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Gynecol Oncol (1995) 1.44
beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev (1996) 1.43
Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol (1990) 1.42
Gravlee Jet Washer effectiveness as performed by obstetric-gynecologic paramedical personnel. Am J Obstet Gynecol (1973) 1.41
Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem (1992) 1.40
Hormone replacement therapy in breast cancer. Lancet (1993) 1.39
Verruciform xanthoma of the ear with coexisting epidermal dysplasia. Am J Dermatopathol (1992) 1.39
Bilateral pheochromocytoma in pregnancy heralding multiple endocrine neoplasia syndrome IIA. A case report. J Reprod Med (2001) 1.39
Inhibition of pseudocholinesterase activity protects from cocaine-induced cardiorespiratory toxicity in rats. J Lab Clin Med (1992) 1.38
Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol (1984) 1.33
Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol (1985) 1.32
Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep (1987) 1.28
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1997) 1.26
Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol (1977) 1.26
Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control (1993) 1.26
Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy. Gynecol Oncol (1997) 1.26
Malignant germ cell tumors of the ovary. Obstet Gynecol (2000) 1.25
Chimeric genetics with beta-galactosidase. Gene Amplif Anal (1983) 1.24
Mutagenesis and mutation transfer induced by ultraviolet light in plasmid-cloned DNA. Gene (1984) 1.24
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (1995) 1.23
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol (1989) 1.22
Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol (1998) 1.21
Sarcoma of the vulva. Report of 12 patients. Obstet Gynecol (1971) 1.19
An alternate approach to early cancer of the vulva. Am J Obstet Gynecol (1979) 1.17
Tumour immunology and evolution of the placenta. Lancet (1970) 1.17
Carcinoembryonic antigen in cancer of the female reproductive system. Serial plasma values correlated with disease state. Cancer (1977) 1.16
Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol (1997) 1.14
Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol (2001) 1.14
Re-irradiation with interstitial implant for recurrent pelvic malignancies. Cancer (1982) 1.13
A plasmid vector for cloning and expression of gene segments: expression of an HTLV-I envelope gene segment. Gene (1986) 1.10
Adenocarcinoma of the cervix associated with human papillomavirus. Cancer (1988) 1.09
Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev (1993) 1.09
A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (2001) 1.06
Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep (1986) 1.06
A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1989) 1.06
Correlation between in vitro drug response in the EDR assay and response to primary paclitaxel and cisplatin. Gynecol Oncol (1999) 1.05
Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis (2000) 1.04
Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol (1995) 1.04
Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol (1992) 1.02
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem J (1993) 1.01
Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol (1989) 1.00
Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol (1994) 1.00
Effect of breast-feeding on postpartum menstruation, ovulation, and pregnancy in Alaskan Eskimos. Am J Obstet Gynecol (1972) 0.99
Facilitation of recovery from inactivation by external Na+ and location of the activation gate in neuronal Na+ channels. J Neurosci (2000) 0.98
Enzyme induction by enflurane in man. Anesthesiology (1976) 0.97
Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol (1996) 0.95
Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol (1993) 0.95
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (1989) 0.94
Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology. Hum Pathol (1991) 0.94
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol (1994) 0.94
Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol (2000) 0.93
Carcinoembryonic antigen in patients with gynecologic malignancies. Am J Obstet Gynecol (1975) 0.93